GENTIAN DIAGNOSTICS ASA (GENT.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:GENT - NO0010748866 - Common Stock
57 NOK
-1.8 (-3.06%)
Overall GENT gets a fundamental rating of 6 out of 10. We evaluated GENT against 67 industry peers in the Health Care Equipment & Supplies industry. While GENT has a great health rating, its profitability is only average at the moment. GENT is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
- In the past year GENT was profitable.
- GENT had a positive operating cash flow in the past year.
- In the past 5 years GENT reported 4 times negative net income.
- In multiple years GENT reported negative operating cash flow during the last 5 years.
1.2 Ratios
- GENT's Return On Assets of 18.38% is amongst the best of the industry. GENT outperforms 97.01% of its industry peers.
- GENT has a Return On Equity of 21.18%. This is amongst the best in the industry. GENT outperforms 88.06% of its industry peers.
- The Return On Invested Capital of GENT (8.76%) is better than 73.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.38% | ||
| ROE | 21.18% | ||
| ROIC | 8.76% |
ROA(3y)0.42%
ROA(5y)-3.57%
ROE(3y)0.25%
ROE(5y)-4.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of GENT (24.80%) is better than 95.52% of its industry peers.
- GENT's Operating Margin of 13.44% is in line compared to the rest of the industry. GENT outperforms 59.70% of its industry peers.
- With a Gross Margin value of 55.06%, GENT perfoms like the industry average, outperforming 47.76% of the companies in the same industry.
- GENT's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.44% | ||
| PM (TTM) | 24.8% | ||
| GM | 55.06% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.26%
GM growth 5Y-7.11%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), GENT is creating some value.
- The number of shares outstanding for GENT remains at a similar level compared to 1 year ago.
- GENT has about the same amout of shares outstanding than it did 5 years ago.
- Compared to 1 year ago, GENT has an improved debt to assets ratio.
2.2 Solvency
- GENT has an Altman-Z score of 18.85. This indicates that GENT is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of GENT (18.85) is better than 98.51% of its industry peers.
- The Debt to FCF ratio of GENT is 0.59, which is an excellent value as it means it would take GENT, only 0.59 years of fcf income to pay off all of its debts.
- GENT has a better Debt to FCF ratio (0.59) than 94.03% of its industry peers.
- GENT has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
- With an excellent Debt to Equity ratio value of 0.01, GENT belongs to the best of the industry, outperforming 91.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.59 | ||
| Altman-Z | 18.85 |
ROIC/WACC1.03
WACC8.51%
2.3 Liquidity
- A Current Ratio of 5.98 indicates that GENT has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 5.98, GENT belongs to the top of the industry, outperforming 98.51% of the companies in the same industry.
- A Quick Ratio of 4.16 indicates that GENT has no problem at all paying its short term obligations.
- GENT's Quick ratio of 4.16 is amongst the best of the industry. GENT outperforms 94.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.98 | ||
| Quick Ratio | 4.16 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 2066.40% over the past year.
- The Revenue has grown by 17.42% in the past year. This is quite good.
- Measured over the past years, GENT shows a very strong growth in Revenue. The Revenue has been growing by 25.96% on average per year.
EPS 1Y (TTM)2066.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.54%
Revenue 1Y (TTM)17.42%
Revenue growth 3Y22.3%
Revenue growth 5Y25.96%
Sales Q2Q%27.94%
3.2 Future
- Based on estimates for the next years, GENT will show a very strong growth in Earnings Per Share. The EPS will grow by 62.29% on average per year.
- Based on estimates for the next years, GENT will show a very strong growth in Revenue. The Revenue will grow by 31.72% on average per year.
EPS Next Y59.41%
EPS Next 2Y62.29%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year31.13%
Revenue Next 2Y31.72%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 20.88, GENT is valued on the expensive side.
- Compared to the rest of the industry, the Price/Earnings ratio of GENT indicates a rather cheap valuation: GENT is cheaper than 82.09% of the companies listed in the same industry.
- GENT is valuated rather cheaply when we compare the Price/Earnings ratio to 26.94, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 21.01, the valuation of GENT can be described as rather expensive.
- The rest of the industry has a similar Price/Forward Earnings ratio as GENT.
- The average S&P500 Price/Forward Earnings ratio is at 23.94. GENT is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.88 | ||
| Fwd PE | 21.01 |
4.2 Price Multiples
- 61.19% of the companies in the same industry are cheaper than GENT, based on the Enterprise Value to EBITDA ratio.
- GENT's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. GENT is more expensive than 62.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 270.53 | ||
| EV/EBITDA | 25.51 |
4.3 Compensation for Growth
- GENT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as GENT's earnings are expected to grow with 62.29% in the coming years.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y62.29%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- With a yearly dividend of 0.68%, GENT is not a good candidate for dividend investing.
- GENT's Dividend Yield is comparable with the industry average which is at 0.95.
- Compared to an average S&P500 Dividend Yield of 1.83, GENT's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.68% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y62.29%
EPS Next 3YN/A
OSL:GENT (1/20/2026, 7:00:00 PM)
57
-1.8 (-3.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners39.37%
Inst Owner ChangeN/A
Ins Owners2.6%
Ins Owner ChangeN/A
Market Cap878.94M
Revenue(TTM)172.52M
Net Income(TTM)42.78M
Analysts85.71
Price Target68.34 (19.89%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.68% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.88 | ||
| Fwd PE | 21.01 | ||
| P/S | 5.09 | ||
| P/FCF | 270.53 | ||
| P/OCF | 70.88 | ||
| P/B | 4.35 | ||
| P/tB | 5.18 | ||
| EV/EBITDA | 25.51 |
EPS(TTM)2.73
EY4.79%
EPS(NY)2.71
Fwd EY4.76%
FCF(TTM)0.21
FCFY0.37%
OCF(TTM)0.8
OCFY1.41%
SpS11.19
BVpS13.1
TBVpS11.01
PEG (NY)0.35
PEG (5Y)N/A
Graham Number28.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.38% | ||
| ROE | 21.18% | ||
| ROCE | 11.37% | ||
| ROIC | 8.76% | ||
| ROICexc | 15.22% | ||
| ROICexgc | 21.01% | ||
| OM | 13.44% | ||
| PM (TTM) | 24.8% | ||
| GM | 55.06% | ||
| FCFM | 1.88% |
ROA(3y)0.42%
ROA(5y)-3.57%
ROE(3y)0.25%
ROE(5y)-4.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.26%
GM growth 5Y-7.11%
F-Score5
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.59 | ||
| Debt/EBITDA | 0.06 | ||
| Cap/Depr | 101.32% | ||
| Cap/Sales | 5.3% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 38.48% | ||
| Profit Quality | 7.6% | ||
| Current Ratio | 5.98 | ||
| Quick Ratio | 4.16 | ||
| Altman-Z | 18.85 |
F-Score5
WACC8.51%
ROIC/WACC1.03
Cap/Depr(3y)104.09%
Cap/Depr(5y)116.83%
Cap/Sales(3y)8.32%
Cap/Sales(5y)10.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2066.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.54%
EPS Next Y59.41%
EPS Next 2Y62.29%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.42%
Revenue growth 3Y22.3%
Revenue growth 5Y25.96%
Sales Q2Q%27.94%
Revenue Next Year31.13%
Revenue Next 2Y31.72%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y260.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year215.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y127.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y285.08%
OCF growth 3YN/A
OCF growth 5YN/A
GENTIAN DIAGNOSTICS ASA / GENT.OL FAQ
Can you provide the ChartMill fundamental rating for GENTIAN DIAGNOSTICS ASA?
ChartMill assigns a fundamental rating of 6 / 10 to GENT.OL.
Can you provide the valuation status for GENTIAN DIAGNOSTICS ASA?
ChartMill assigns a valuation rating of 4 / 10 to GENTIAN DIAGNOSTICS ASA (GENT.OL). This can be considered as Fairly Valued.
Can you provide the profitability details for GENTIAN DIAGNOSTICS ASA?
GENTIAN DIAGNOSTICS ASA (GENT.OL) has a profitability rating of 4 / 10.
How financially healthy is GENTIAN DIAGNOSTICS ASA?
The financial health rating of GENTIAN DIAGNOSTICS ASA (GENT.OL) is 9 / 10.
What is the earnings growth outlook for GENTIAN DIAGNOSTICS ASA?
The Earnings per Share (EPS) of GENTIAN DIAGNOSTICS ASA (GENT.OL) is expected to grow by 59.41% in the next year.